Seed Therapeutics
- Biotech or pharma, therapeutic R&D
SEED Therapeutics is a preclinical stage biotech focused on developing and utilizing its proprietary RITE3 platform to discover and develop a pipeline of targeted protein degradation agents to improve human health. SEED's pipeline includes wholly owned projects, as well as projects partnered with Eli Lilly and Company or Eisai. At BIO, SEED is interested in meeting to discuss the following opportunities for investment and collaboration:
- Opportunity to invest in SEED's ongoing Series A3 raise before clinical testing on SEED's lead asset begins;
- Opportunity to partner on the development of our patented PROTAC combination strategy, to overcome challenges with PROTAC monotherapy;
- Opportunity to collaborate on the discovery of molecular glues targeting disease-causing proteins for degradation, utilizing SEED's proprietary RITE3 platform.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}